In the long history of human beings, we have been seriously affected many times by infectious diseases.
After the existence of the causative agents of infectious diseases was discovered in the 19th century, tremendous amounts of effort has been taken to overcome incurable diseases by improving public health, developing vaccines, and in the 1940s, antibiotics were developed for the first time in our history to end this fight.
However, it was the beginning of a new challenge.
With the rapid spread of antibiotics, drug-resistant bacteria emerged, which developed resistance to antibiotics and became less effective. Treatment of drug-resistant bacteria is difficult because existing antibiotics are ineffective, requiring a large number of prescriptions and alternative drugs. This also causes a variety of medical problems, such as increased susceptibility to new infections during surgery or when the immune system is weakened by anticancer drugs.
This is the “Antimicrobial Resistance(AMR)” problem.
According to a report by the United Nations, if appropriate measures are not taken to address the AMR problem, it is estimated that the number of global deaths due to AMR will exceed 10 million by 2050, and the estimated cumulative production loss will be up to 100 trillion dollars worldwide.
In order to solve this problem, it is important to correctly diagnose infectious diseases and treat them with appropriate doses of antibiotics. However, in the real world, it is difficult for all medical institutions (hospitals, doctor offices, clinics etc) to make adequate investments for accurate and rapid diagnosis due to resource constraints.
We started CarbGeM with the mission of addressing these challenges.
CarbGeM aims to overcome this problem through the application of cutting-edge biology and digital technology, cross-industrial and cross-disciplinary collaboration including medicine and engineering, and industry-government-academia collaboration with leading research institutions in Japan and abroad.
There is a limit to what we, as a venture company, can be done alone. We would like to continue to learn, grow, and strive for building a safer society with people who share our visions.
We want to continue to be a place where not only our employees, but also all of the members who work with us can grow, play an active role, and be rewarded for their contributions. We aim to be a company that is attractive to professionals in their respective fields who share the same sense of mission.
Representative Director, CEO Masakazu Nakajima
Based on our vision of “realizing next-generation medical innovation through the fusion of cutting-edge bio-digital technologies and creating a platform on which many researchers can work”, we aim to realize “a society in which all people can receive high-quality medical care” and “a society in which innovation is created in a sustainable manner”. We are promoting the following activities.
We believe that these efforts will lead to the achievement of the SDGs, which consist of 17 goals, and we will actively contribute to the achievement of the SDGs through the following specific efforts.
By integrating our cutting-edge bio-digital technologies, we will contribute to a society in which all people can receive high quality medical care by providing innovative solutions in each phase of medical care: prevention, diagnosis, and treatment.
Specifically, we will tackle social and global medical issues such as antimicrobial resistance.
By utilizing our cutting-edge bio-digital technology, we aim to achieve a higher level of economic productivity by reforming the medical field, which tends to be labor-intensive, in addition to providing high added medical value.
Specifically, we will promote digital experience (DX) to reduce the burden on medical workplaces by utilizing the latest digital technologies such as AI and cloud computing.
We aim to promote scientific research in the healthcare industry sector in all countries, including developing countries, to improve technological capabilities, and ultimately to develop affordable, high-quality medical technology, by promoting public-private research-driven innovation and by working to improve the number of young R&D workers who will lead the next generation and significantly increase the number of young R&D workers.
Specifically, we will create an environment where people can play an active role in technology creation by collaborating with industry, government, and academia to create innovations on their own, building a collaborative platform to accelerate innovation based on their experiences, and in addition, actively promoting young researchers of the next generation and building a connection platform.
20+ years experience in business development, venture capital/private equity investments and cross-border M&As at multinational corporations as well as startups, including ITOCHU, Cyber Agent, Schroder Ventures, Macquarie Capital. Also has entrepreneurial experience in healthcare /medical startups, including Welby Inc. (TSE: 4438) (co-founder, ex-CFO) and NextGeM (co-founder, CEO). B. Eng. in Mechanical Engineering.
20+ years of experience in solution development in particular machine learning /Deep learning for NTT Data, Cyber Agent, MUFG Bank and NextGem. MS in Electrical Engineering.
Mac has over 35 years management experience in research and product development at Panasonic and Nihon Kohden. During his over 20 years tenure in the US, Mac has conducted many collaborative research projects with top universities and hospitals including MIT, Harvard Medical School, Massachusetts General Hospital, University of Pennsylvania Medical School, Children’s Hospital of Philadelphia and University of California. Mac was also a co-founder of a drug discovery start-up, Tensor Biosciences, in California. He returned to Japan in 2016 as General Manager of RIKEN (Japanese national research center) and then moved to Osaka University in 2020 as General Manager & Project Researcher, Initiative for Life Design Innovation Strategic Office. BS and MS, Osaka University, Ph.D. Nagoya City University Medical School. He has been a Director of NextGeM since April 2020.
After graduating from International Christian University, Chiamin joined Intentia, a major ERP vendor, working on corporate digitization and operational reforms projects across Japan and Europe. She then worked for a U.S. strategy consulting firm, Monitor Group, overseeing business strategy planning and Asian expansion projects, before joining DCM Ventures as a venture capitalist, where she was in charge of investments into startups such as freee and Coubic, etc. In 2014, she joined Happy Elements, a Chinese startup, serving as Chief Strategy Officer and in charge of their listing in Japan, before becoming the Representative Director of Japan, overseeing content development and AR/VR businesses in Japan and China. Chiamin joins UB Ventures as a Managing Partner since 2021. Chiamin has an MBA from IE Business School.
April 2017 -, Attending physician, Disease Control and Prevention Center(Department of Infectious diseases, Travel Clinic), National Center for Global Health and Medicine, Japan
April 2014 – March 2017, Fellow, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan
April 2011 – March 2014, Fellow, Department of Infectious Diseases, National Center for Global Health and Medicine, Japan
April 2008 – March 2011, Senior resident, General pediatrics Kanagawa Children’s Medical Center, Japan
April 2006 – March 2008, Resident Chigasaki Tokushukai Medical Center, Japan
2018 October; Board Certified Member of the Japanese Society of Internal Medicine
2017 Certificated Infection Control Doctor of the Japanese Society for Infectionn Prevention and Control
2015 May; Certificate in Travel Health, International Society of Travel Medicine
2015 January; Board Certified Infectious Diseases physician of the Japanese Association for Infectious Diseases
2011 December; Board Certified Pediatrician of the Japanese Pediatric Society
Associate professor, Division of Infectious Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Graduate School of Medicine
Vice Chief, Department of Clinical Laboratory, Kobe University Hospital
2008-2009 Vice chief,Division of Infectious Diseases, Department of Infectious Disease and General Medicine, Kameda Medical Center
Sep 2001 Board Certified Member of the Japanese Society of Internal Medicine.
Dec 2004 Fellow of the Japanese Society of Internal Medicine
May 2005 Fellow of the Japanese Society of Gastroenterology
Dec 2005 Board Certified Fellow of the Japan Gastroenterological Endoscopy Society
Jan 2007 Registered Doctor, the Japanese Association for Infectious Diseases
Assistant Professor and Attending Physician, Department of Emergency Medicine, North Shore University Hospital, LIJ Medical Center, Donald and Barbara Zucker School of Medicine at Hofstra, and Institute of Molecular Medicine, The Feinstein Institutes for Medical Research/Northwell Health
He is specialized in expertise including post-cardiac arrest syndrome, ischemia-reperfusion injury, mitochondrial dysfunction, and oxygen metabolism. He has published more than 70 papers in international journals in the emergency and critical care medicine field. In addition to his outstanding achievements as a clinician, he conducts clinical and basic research in the latest fields integrating medical and science.
2021 – present, Assistant Professor (Institute of Molecular Medicine), The Feinstein Institute for Medical Research, and the Donald and Barbara Zucker School of Medicine (Emergency Medicine) at Hofstra/Northwell Health, NY, US
Attending Physician, North Shore University Hospital and Long Island Jewish Medical Center/Northwell Health, NY, US
2018 – 2021, Resident (Emergency Medicine), North Shore University Hospital: Manhasset, NY, US
2015 – 2018, Institute Scientist (Department of Emergency Med-Cardiopulmonary), Feinstein Institute for Medical Research: Manhasset, NY, US
2013 – 2015, Research Fellow, Center for Resuscitation Science, University of Pennsylvania, US
2002 – 2013, Medical Doctor, Department of Emergency and Critical Care Medicine, Chiba University, JP
2009, PhD, Graduate School of Medicine and Pharmaceutical Science, Chiba University, JP
2002, MD, School of Medicine, Chiba University, JP
Joined CyberAgent Inc. in 2004 after working experience some contract development. Responsible for developing new business launch such as various media and social apps. Joined Mercari Inc. in 2016. Transferred to the US department, took charge of service development of the US, and became CTO of Mercari Inc.
|Company Name||CarbGeM Inc.
CarbGeM = Combating Antibiotic-Resistant Bacteria by next Generation of Medical Device
|Representative Director of the Board||Masakazu Nakajima|
|Shareholders||NextGeM Inc.、Board Members、UB Ventures, Inc|
|Headquarters||1-5-13 Jinnan, Shibuya-ku, Tokyo 150-0041|
|Bio Research Lab.||6-3-7 Minatojima Minamimachi, Chuo-ku, Kobe-shi, Hyogo 650-0047|
|Business purpose||Research and development of next-generation medical-related technologies in the field of infectious diseases|
|Member Association||Japan Association for the Advancement of Medical Equipment (JAAME)|